Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)

CAPS Rating: 3 out of 5

A clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases.


Player Avatar apoolla13 (< 20) Submitted: 1/29/2013 10:40:31 AM : Outperform Start Price: $8.44 ARNA Score: +1.66

Fundamentally there are couple of strong analysts - EU approval, Q1 sales figures and finally acceptance of Belviq as an OTC drug by the general populace. My exit point is at Q1 sales figures.

Featured Broker Partners